Blood Pressure Management in Elderly Patients with CKD and CHF

Introduction to Blood Pressure Goals

• The American College of Cardiology recommends a blood pressure goal of <130/80 mmHg for patients with stage 3 CKD and CHF, as this target reduces cardiovascular mortality and all-cause death 1, 2, 3
• The American College of Cardiology guidelines establish that patients with stage 3 CKD have an automatic 10-year ASCVD risk ≥10%, placing them in the high-risk category requiring BP <130/80 mmHg 1, 2, 3, 4, 5

Rationale for Aggressive Blood Pressure Control

• Stage 3 CKD patients comprised 28% of the SPRINT study population, where intensive BP management provided the same cardiovascular and mortality benefits as seen in the full cohort 1, 2, 3, 4, 5
• Given that most CKD patients die from cardiovascular complications rather than progressing to ESRD, the cardiovascular benefit of lower BP targets takes priority 1, 2, 3, 4, 5

Considerations for Elderly Patients

• The American College of Cardiology recommends SBP <130 mmHg for noninstitutionalized, ambulatory, community-dwelling adults ≥65 years if tolerated 1, 6
• In SPRINT's prespecified subgroup analysis, frail elderly patients (≥75 years) sustained benefit from the lower BP target, including those with the slowest gait speed 1, 2, 3, 4, 5

Implementation of Blood Pressure Management

• Initiate or optimize an ACE inhibitor or ARB as first-line therapy, as this patient likely has or will develop albuminuria given the CKD and CHF 1, 2, 3, 4, 5, 9
• Add a diuretic as second-line therapy, which is particularly important given the CHF diagnosis 1, 2, 3
• Consider additional agents (beta-blockers for CHF, calcium channel blockers) as needed to reach target 1, 2, 3

Monitoring and Adjustments

• Check BP, serum creatinine, and potassium within 2-4 weeks of initiating or increasing ACE inhibitor/ARB dose 9
• Continue therapy unless creatinine rises >30% within 4 weeks of initiation or dose increase 9
• Monitor carefully for orthostatic hypotension, which is more common in elderly patients 6
• Watch for symptomatic hypotension and electrolyte abnormalities, particularly hyperkalemia 1, 2, 3, 9

Important Caveats and Contraindications

• Never combine ACE inhibitor + ARB, as this increases adverse effects without additional benefits 1, 2, 3, 4, 5, 9
• Avoid ACE inhibitor or ARB combined with direct renin inhibitors 1, 2, 3, 4, 5, 9

Prioritization of Mortality Reduction

• The primary concern for this 81-year-old with stage 3 CKD and CHF is cardiovascular death, not progression to ESRD 1, 2, 3, 4, 5
• SPRINT demonstrated clear mortality benefit with intensive BP control in exactly this patient population (elderly, CKD, high cardiovascular risk) 1, 2, 3